PCI Biotech downsizes staff, winds down operations amid strategic shift

PCI Biotech announced a downsizing of personnel and an extended wind-down of operations, aligning with a new focus on evaluating an undisclosed bioprocessing technology. This decision follows the August 2025 discontinuation of its PCL technology development due to insufficient progress and unacceptable project risk.

The company's immediate priority has been to preserve value through an evaluation of strategic alternatives, including reverse mergers or a structured wind-down. The current technology evaluation is being conducted under a material transfer agreement with no financial terms.

This strategic evaluation process continues in parallel with the bioprocessing technology assessment. Further updates are expected as the company navigates its future operations.